Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner

Fig. 3

AhR collaborated with NF-κB to facilitate the activation of c-Myc. A, immunofluorescence staining of AhR and NF-κB in LNCaP cells treated with PBS or Kyn (200 μM). The scale bar was 15 μm. B, western blotting of c-Myc in LNCaP/VCaP cells treated with PBS, Kyn (200 μM) and Kyn (200 μM) combing AhR antagonist 2 (2 nM). C, western blotting of c-Myc in LNCaP/VCaP cells treated with Kyn (200 μM) and Kyn (200 μM) combing PA (10 μM). D, cytotoxicity of Kyn (200 μM) cultured LNCaP/VCaP cells treated with PBS or Mycro 3 (1 μM) to Abi (10 μM). E, cytotoxicity of Kyn (200 μM) cultured LNCaP/VCaP cells treated with PBS or Mycro 3 (1 μM) to Doc (1 μg/ml). F, immunofluorescence staining of c-Myc in prostatic tumor tissues from chemo-sensitive (C-S) and chemo-resistant (C-R) patients (n = 10 per groups). The scale bar was 15 μm. G, the overall survival of patients with prostate cancer in high c-Myc expression and low c-Myc expression (n = 275)

Back to article page